Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Aacr Nci Eortc International Conference Molecular Targets And Cancer Therapeutics
Download Aacr Nci Eortc International Conference Molecular Targets And Cancer Therapeutics full books in PDF, epub, and Kindle. Read online Aacr Nci Eortc International Conference Molecular Targets And Cancer Therapeutics ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author :Francesco M. Veronese Publisher :Springer Science & Business Media ISBN 13 :3764386797 Total Pages :289 pages Book Rating :4.7/5 (643 download)
Book Synopsis PEGylated Protein Drugs: Basic Science and Clinical Applications by : Francesco M. Veronese
Download or read book PEGylated Protein Drugs: Basic Science and Clinical Applications written by Francesco M. Veronese and published by Springer Science & Business Media. This book was released on 2009-12-30 with total page 289 pages. Available in PDF, EPUB and Kindle. Book excerpt: PEGylation technology and key applications are introduced by this topical volume. Basic physical and chemical properties of PEG as basis for altering/improving in vivo behaviour of PEG-conjugates such as increased stability, improved PK/PD, and decreased immunogenicity, are discussed. Furthermore, chemical and enzymatic strategies for the coupling and the conjugate characterization are reported. Following chapters describe approved and marketed PEG-proteins and PEG-oligonucleotides as well as conjugates in various stages of clinical development.
Book Synopsis Molecular Oncology by : Frank Joseph Rauscher (III)
Download or read book Molecular Oncology written by Frank Joseph Rauscher (III) and published by Cambridge University Press. This book was released on 2014 with total page 985 pages. Available in PDF, EPUB and Kindle. Book excerpt: Reviews the origins of molecular oncology, including technologies for cancer analysis, key pathways in human malignancies, and available pharmacologic therapies.
Book Synopsis Molecular Targeting in Oncology by : Howard L. Kaufman
Download or read book Molecular Targeting in Oncology written by Howard L. Kaufman and published by Springer Science & Business Media. This book was released on 2007-12-26 with total page 719 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book presents an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer. It is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice.
Book Synopsis Clinical Trials in Oncology, Third Edition by : Stephanie Green
Download or read book Clinical Trials in Oncology, Third Edition written by Stephanie Green and published by CRC Press. This book was released on 2012-05-09 with total page 266 pages. Available in PDF, EPUB and Kindle. Book excerpt: The third edition of the bestselling Clinical Trials in Oncology provides a concise, nontechnical, and thoroughly up-to-date review of methods and issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have separate chapters and expanded discussions on general clinical trials issues, and issues specific to Phases I, II, and III. New sections cover innovations in Phase I designs, randomized Phase II designs, and overcoming the challenges of array data. Although this book focuses on cancer trials, the same issues and concepts are important in any clinical setting. As always, the authors use clear, lucid prose and a multitude of real-world examples to convey the principles of successful trials without the need for a strong statistics or mathematics background. Armed with Clinical Trials in Oncology, Third Edition, clinicians and statisticians can avoid the many hazards that can jeopardize the success of a trial.
Book Synopsis Accounts in Drug Discovery by : Joel Barrish
Download or read book Accounts in Drug Discovery written by Joel Barrish and published by Royal Society of Chemistry. This book was released on 2011 with total page 397 pages. Available in PDF, EPUB and Kindle. Book excerpt: Accounts in Drug Discovery describes recent case studies in medicinal chemistry with a particular emphasis on how the inevitable problems that arise during any project can be surmounted or overcome. The Editors cover a wide range of therapeutic areas and medicinal chemistry strategies, including lead optimization starting from high-throughput screening "hits" as well as rational, structure-based design. The chapters include "follow-ons" and "next generation" compounds that aim to improve upon first-generation agents. This volume surveys the range of challenges commonly faced by medicinal chemistry researchers, including the optimization of metabolism and pharmacokinetics, toxicology, pharmaceutics and pharmacology, including proof-of-concept in the clinic for novel biological targets. The case studies include medicinal chemistry stories on recently approved and marketed drugs, but also chronicle "near-misses," i.e. exemplary compounds that may have proceeded well into the clinic but for various reasons did not result in a successful registration. As the vast majority of projects fail prior to registration, much can be learned from such narratives. By sharing a wide range of drug discovery experiences and information across the community of medicinal chemists in both industry and academia, the Editors believe that these accounts will provide insights into the art of medicinal chemistry as it is currently practiced and will help to serve the needs of active medicinal chemists.
Download or read book Oncogenomics written by Franco Dammacco and published by Academic Press. This book was released on 2018-10-30 with total page 722 pages. Available in PDF, EPUB and Kindle. Book excerpt: Oncogenomics: From Basic Research to Precision Medicine offers a thorough survey of precision medicine and its diagnostic and therapeutic applications in oncology. Gathering contributions from leading international researchers in the field, chapters examine recent translational advances in oncogenomic methods and technologies, detailing novel molecular classifications of tumors as well as diagnostic and prognostic biomarkers for various types of cancers including pancreatic, gastrointestinal, breast, hematological, lung, osteotropic, genitourinary, and skin cancers. This book provides a foundation for clinical oncologists, human geneticists, and physicians to develop new targeted cancer treatments and incorporate genomic medicine into clinical practice, with particular attention paid to noninvasive diagnostic techniques such as the liquid biopsy and molecular characterization of solid malignancies. - Provides clinical oncologists, human geneticists, physicians, and students with a thorough understanding of current diagnostic and prognostic applications of genomic methods and technologies to a variety of solid malignancies - Employs current knowledge in oncogenomics towards developing therapeutic interventions for various cancer types - Features a team of internationally recognized researchers and physicians in clinical oncology, oncogenomics and precision medicine
Book Synopsis Edible Medicinal and Non-Medicinal Plants by : T. K. Lim
Download or read book Edible Medicinal and Non-Medicinal Plants written by T. K. Lim and published by Springer. This book was released on 2016-02-02 with total page 670 pages. Available in PDF, EPUB and Kindle. Book excerpt: Volume 10 is part of a multi compendium Edible Medicinal and Non-Medicinal Plants. This work is of significant interest to medical practitioners, pharmacologists, ethnobotanists, horticulturists, food nutritionists, botanists, agriculturists, conservationists and general public. 59 plant species with edible modified stems, roots and bulbs in the families Amaranthaceae, Cannaceae, Cibotiaceae, Convolvulaceae, Cyperaceae, Dioscoreaceae, Euphorbiaceae, Fabaceae, Iridaceae, Lamiaceae, Marantaceae, Nelumbonaceae, Nyctaginaceae, Nymphaeaceae, Orchidaceae, Oxalidaceae, Piperaceae, Poaceae, Rubiaceae, Simaroubaceae, Solanaceae, Tropaeolaceae, Typhaceae and Zingiberaceae. Topics covered include: taxonomy; common/ vernacular names; origin/ distribution; agroecology; edible plant parts/uses; botany; nutritive/medicinal properties, nonedible uses and selected references.
Book Synopsis Antibody-Drug Conjugates and Immunotoxins by : Gail Lewis Phillips
Download or read book Antibody-Drug Conjugates and Immunotoxins written by Gail Lewis Phillips and published by Springer Science & Business Media. This book was released on 2012-12-13 with total page 370 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Book Synopsis Innovations for Next-Generation Antibody-Drug Conjugates by : Marc Damelin
Download or read book Innovations for Next-Generation Antibody-Drug Conjugates written by Marc Damelin and published by Springer. This book was released on 2018-05-29 with total page 358 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Download or read book Biobetters written by Amy Rosenberg and published by Springer. This book was released on 2015-08-21 with total page 384 pages. Available in PDF, EPUB and Kindle. Book excerpt: “Biobetters: Protein Engineering to Approach the Curative” discusses the optimization of protein therapeutic products for treatment of human diseases. It is based on the fact that though numerous important therapeutic protein products have been developed for life threatening and chronic diseases that possess acceptable safety and efficacy profiles, these products have generally not been reexamined and modified for an improved clinical performance, with enhancements both to safety and efficacy profiles. Advances in protein engineering, coupled with greatly enhanced understanding of critical product quality attributes for efficacy and safety, make it possible to optimize predecessor products for clinical performance, thereby enhancing patient quality of life and with the potential for great savings in health care costs. Yet despite such knowledge, there is little movement towards such modifications. This book examines engineering protein therapeutic products such that they exhibit an optimal, not just an adequate, clinical performance profile. Two product classes, therapeutic enzymes for lysosomal storage diseases (enzyme replacement therapies, ERT) and monoclonal antibodies (mAbs), are used as examples of what modifications to such proteins could be made to enhance clinical performance, “closer to a cure” as it were. For ERT, the key to optimizing clinical performance is to ensure the ERT is endowed with moieties that target the protein to the relevant target tissue. Thus, for Gaucher Disease, our best example of how to optimize an ERT to address a disease that manifests in specific target tissues (macrophages and monocytes), the enzyme has been extensively modified to target macrophages. For diseases such as Pompe Disease, largely a disorder of muscle, optimal performance of ERT will depend on endowing the enzyme with the ability to be taken up via the Mannose 6 Phosphate Receptor, and so one of the chapters in the book will discuss such approaches. Moreover, a major failure of biotechnology based products is to gain access to the CNS, a key target tissue in numerous diseases. Thus, a chapter has been devoted to strategies to access the CNS. Additionally, immune responses to therapeutic proteins can be highly problematic, eliminating the efficacy of life saving or highly effective protein therapeutics. This is especially poignant in the case of Pompe Disease wherein great improvement in muscle strength and functionality is lost following development of an immune response to the ERT with consequent patient deterioration and death. Thus, a chapter regarding protein engineering, as well as other non-clinical approaches to diminishing immunogenicity is a valuable part of the book. Monoclonal antibodies (mAbs) can be engineered to bind targets relevant to a wide variety of diseases; binding affinity, however, is only part of the equation and one of the chapters will present a molecular assessment approach that balances affinity with pharmacokinetics and manufacturability. As with other proteins immunogenicity can be problematic, being responsible for loss of efficacy of anti-TNF mAbs, often after prolonged successful treatment. The authors will also share their perspective on the consequences of physico-chemical modifications occurring to mAbs once they reach the circulation or their target, a research area open to further development from a protein engineering as well as analytical perspective. This book will also discuss novel platforms for protein therapeutics, technologies that exceed mAbs with respect to potency, and hence, potentially efficacy. These platforms consist largely of repeat domain proteins with very high affinity for their target ligands, but while potentially more efficacious, immunogenicity may be a major problem limiting use. The economics surrounding the issue of biobetters is another high-profile issue - this final chapter will explore the incentives and disincentives for developing biobetters and consider incentives that might make their pursuit more rewarding.
Book Synopsis Single-Arm Phase II Survival Trial Design by : Jianrong Wu
Download or read book Single-Arm Phase II Survival Trial Design written by Jianrong Wu and published by CRC Press. This book was released on 2021-08-06 with total page 225 pages. Available in PDF, EPUB and Kindle. Book excerpt: Single-Arm Phase II Survival Trial Design provides a comprehensive summary to the most commonly- used methods for single-arm phase II trial design with time-to-event endpoints. Single-arm phase II trials are a key component for successfully developing advanced cancer drugs and treatments, particular for target therapy and immunotherapy in which time-to-event endpoints are often the primary endpoints. Most test statistics for single-arm phase II trial design with time-to-event endpoints are not available in commercial software. Key Features: Covers the most frequently used methods for single-arm phase II trial design with time-to-event endpoints in a comprehensive fashion. Provides new material on phase II immunotherapy trial design and phase II trial design with TTP ratio endpoint. Illustrates trial designs by real clinical trial examples Includes R code for all methods proposed in the book, enabling straightforward sample size calculation.
Book Synopsis Molecules of Nature by : Paul F. Torrence
Download or read book Molecules of Nature written by Paul F. Torrence and published by Dog Ear Publishing. This book was released on 2017-12-13 with total page 300 pages. Available in PDF, EPUB and Kindle. Book excerpt: Molecules of nature are created by living organisms in their quest to survive and thrive in Earth’s challenging environments. This ages-old evolutionary struggle has produced an immense library of chemicals from which humans have selected invaluable therapeutics critical to modern medicine. Natural products presently provide half of all prescription medications and 70% of all cancer drugs. The success of continued drug development from natural products depends upon the diversity of molecules of nature, which in turn depends upon biodiversity. Unfortunately, human-caused damage to the environment, from pollution to habitat loss to overexploitation of resources, is causing unprecedented ecological damage and death of species: a mass extinction event. Unless this biotic crisis is obviated, humanity will lose a primary source of future novel medicines. This book assembles a powerful argument for nature’s critical role in providing medicines for humanity and how that irreplaceable service is threatened by the extinction crisis. A sampling of the molecules of nature employed in modern medicine reads like a catalog of biodiversity. For example, one of the most prescribed drugs in the United States is lisinopril, which controls high blood pressure. Lisinopril originated from the venom of a deadly viper from the Amazonian forests. A denizen of US southwestern deserts provided a therapeutic for type-II diabetes. The ancient horseshoe crab of the US Atlantic coast enables a critical test for deadly endotoxins in medical products of all kinds. Once, a diagnosis of acute lymphocytic leukemia in children was a death sentence. A tropical flower from Madagascar provided two natural products that changed a 90% fatality rate to a 90% cure rate. The Pacific Yew tree from the US northwest was discovered to contain the potent anticancer agent Taxol, now vital in the treatment of breast and ovarian cancers and Kaposi’s sarcoma. This book tells the fascinating story of these and other medicines. It also summarizes some of the driving forces of the Sixth Mass Extinction and shows how it threatens at least half of the planet’s species with extinction. We rightly ask: What will be the future of medicine without the contribution of millions of species? How many treatments for disease will be forever lost? What cures are we asking future generations to forgo? As we willy-nilly extinguish the future of one organism after another together with all the knowledge they hold, we are like the looters of the Great Library of Alexandria. The final chapter challenges readers to pursue a different outcome: By uniting our efforts, we can still preserve many of the remaining species on our blue-green planet and the invaluable gifts they offer.
Book Synopsis Signaling Pathways in Squamous Cancer by : Adam B. Glick
Download or read book Signaling Pathways in Squamous Cancer written by Adam B. Glick and published by Springer Science & Business Media. This book was released on 2010-11-25 with total page 471 pages. Available in PDF, EPUB and Kindle. Book excerpt: Squamous epithelia form the lining surface of tissues in contact with the environment: the skin, oral mucosa, esophagus and respiratory tract, the genital tract, and several other specialized tissues. These tissues are at highest risk for exposure to environmental carcinogens such as UV, tobacco smoke and infectious agents. Cancers that form in squamous epithelia are among the most common human solid tumors and have high morbidity and mortality. These cancers include squamous cell carcinoma of the skin, oral cancer, head and neck and esophageal cancer, certain lung cancers and cervical cancer. We propose to organize the book so that the early chapters will focus on individual pathways and more specific mechanisms in both normal function and cancer, while the later chapters will be more integrative and include overviews of biomarkers and therapeutic development. This should increase interest for clinically oriented researchers. All authors will be encouraged to provide a balanced review in addition to highlighting their own work.
Book Synopsis Extracellular Targeting of Cell Signaling in Cancer by : James W. Janetka
Download or read book Extracellular Targeting of Cell Signaling in Cancer written by James W. Janetka and published by John Wiley & Sons. This book was released on 2018-07-23 with total page 482 pages. Available in PDF, EPUB and Kindle. Book excerpt: International experts present innovative therapeutic strategies to treat cancer patients and prevent disease progression Extracellular Targeting of Cell Signaling in Cancer highlights innovative therapeutic strategies to treat cancer metastasis and prevent tumor progression. Currently, there are no drugs available to treat or prevent metastatic cancer other than non-selective, toxic chemotherapy. With contributions from an international panel of experts in the field, the book integrates diverse aspects of biochemistry, molecular biology, protein engineering, proteomics, cell biology, pharmacology, biophysics, structural biology, medicinal chemistry and drug development. A large class of proteins called kinases are enzymes required by cancer cells to grow, proliferate, and survive apoptosis (death) by the immune system. Two important kinases are MET and RON which are receptor tyrosine kinases (RTKs) that initiate cell signaling pathways outside the cell surface in response to extracellular ligands (growth factors.) Both kinases are oncogenes which are required by cancer cells to migrate away from the primary tumor, invade surrounding tissue and metastasize. MET and RON reside on both cancer cells and the support cells surrounding the tumor, called the microenvironment. MET and RON are activated by their particular ligands, the growth factors HGF and MSP, respectively. Blocking MET and RON kinase activation and downstream signaling is a promising therapeutic strategy for preventing tumor progression and metastasis. Written for cancer physicians and biologists as well as drug discovery and development teams in both industry and academia, this is the first book of its kind which explores novel approaches to inhibit MET and RON kinases other than traditional small molecule kinase inhibitors. These new strategies target key tumorigenic processes on the outside of the cell, such as growth factor activation by proteases. These unique strategies have promising potential as an improved alternative to kinase inhibitors, chemotherapy, or radiation treatment.
Book Synopsis Novel Immunotherapeutic Approaches to the Treatment of Cancer by : Paul D. Rennert
Download or read book Novel Immunotherapeutic Approaches to the Treatment of Cancer written by Paul D. Rennert and published by Springer. This book was released on 2016-05-30 with total page 285 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.
Book Synopsis From Molecular to Modular Tumor Therapy: by : Albrecht Reichle
Download or read book From Molecular to Modular Tumor Therapy: written by Albrecht Reichle and published by Springer Science & Business Media. This book was released on 2010-09-09 with total page 552 pages. Available in PDF, EPUB and Kindle. Book excerpt: Presenting a holistic and abstract perspective of tumors, this volume aims to provide personalized diagnostic and therapeutic strategies for the control of metastatic tumor disease. Readers will find ways to record tumor biology that are based on different sciences, in addition to other strategies.
Book Synopsis Principles of Molecular Diagnostics and Personalized Cancer Medicine by : Dongfeng Tan
Download or read book Principles of Molecular Diagnostics and Personalized Cancer Medicine written by Dongfeng Tan and published by Lippincott Williams & Wilkins. This book was released on 2012-12-07 with total page 2177 pages. Available in PDF, EPUB and Kindle. Book excerpt: The role of molecular genetics in the treatment of malignancy continues to grow at an astonishing rate. Today’s subspecialized multidisciplinary approach to oncology has incorporated advances in targeted molecular therapy, prognosis, risk assessment, and prevention—all based at least in part on molecular diagnostics and imaging. Inside this cutting-edge resource, readers will explore broad, comprehensive perspectives on the current trends in molecular diagnosis of cancer and personalized cancer medicine. Authoritative discussions share insights from noted experts in cancer research, clinical trials, molecular diagnostics, personalized therapy, bioinformatics, and federal regulations. From the basic mechanisms of carcinogenesis to the most advanced molecular screening, staging, and treatment technologies, readers will discover clear and straightforward discussions directly relevant to patient diagnosis and care.
